ATOSSA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
ATOSSA THERAPEUTICS, INC. (ATOS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $710.10 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $338.40, a 14.55% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $396.00, a 50.12% decline year-over-year.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $793.83.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $4710.97, a 1725.39% increase from fiscal 2024.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $258.08, a 69.15% decline from fiscal 2023.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $836.63.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $710.10 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $4710.97 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $314.04 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $319.77 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $338.40 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $258.08 10-K · filed 2025-03-25 | |||
| 2024-09-30 | $258.08 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $255.47 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $396.00 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $836.63 10-K · filed 2024-04-01 | |||
| 2023-09-30 | $870.40 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $870.40 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $793.83 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $0.00 10-K · filed 2023-03-22 | |||
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $225.00 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | |||
| 2017-12-31 | $25.05 10-K · filed 2018-03-08 | |||
| 2017-09-30 | $25.05 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $25.05 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $25.05 10-Q · filed 2017-05-11 | |||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | $6.00 10-K · filed 2014-03-27 | |||
| 2013-09-30 | $4.99 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-14 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | $0.00 10-K · filed 2013-03-28 | |||
| 2012-09-30 | $0.00 10-Q/A · filed 2013-01-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |